Sequence Detail

ID/Version

Q07174 (UniProt | EBI)

Last sequence update: 1995-02-01
Last annotation update: 2024-11-27

Sequence description from provider

RecName: Full=Mitogen-activated protein kinase kinase kinase 8; EC=2.7.11.25;AltName: Full=Cancer Osaka thyroid oncogene;AltName: Full=Proto-oncogene c-Cot;AltName: Full=Serine/threonine-protein kinase cot;AltName: Full=Tumor progression locus 2;

Provider

SWISS-PROT

Sequence

Polypeptide 467 aa

Source

Organism mouse

See UniProt | EBI for source

Annotated genes and markers

Follow the symbol links to get more information on the GO terms, expression assays, orthologs, phenotypic alleles, and other information for the genes or markers below.

Type	Symbol	Name	GO Terms	Expression Assays	Orthologs	Phenotypic Alleles
Gene	Map3k8	mitogen-activated protein kinase kinase kinase 8	13	98	3	21

Sequence references in MGI

J:12833 Ohara R, et al., The murine cot proto-oncogene: genome structure and tissue-specific expression. Jpn J Cancer Res. 1993 May;84(5):518-25
J:66503 Dumitru CD, et al., TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000 Dec 22;103(7):1071-83
J:82762 Waterfield MR, et al., NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell. 2003 Mar;11(3):685-94
J:141397 Watford WT, et al., Tpl2 kinase regulates T cell interferon-{gamma} production and host resistance to Toxoplasma gondii. J Exp Med. 2008 Nov 24;205(12):2803-12
J:164170 Jager J, et al., Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes. 2010 Jan;59(1):61-70
J:204505 Das S, et al., Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem. 2005 Jun 24;280(25):23748-57
J:205699 McNab FW, et al., TPL-2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J Immunol. 2013 Aug 15;191(4):1732-43